摘要
目的探讨高压氧联合人尿激肽原酶对急性脑梗死(ACI)患者神经功能缺损程度评分(NIHSS)及血清可溶性细胞间黏附分子-1(sICAM-1)、单核细胞趋化蛋白-1(MCP-1)水平变化的影响。方法选取2015-02—2017-06开封市中心医院ACI患者104例,随机数字表法分为2组各52例。对照组予以常规治疗,观察组于常规治疗基础上采取高压氧联合人尿激肽原酶治疗,均持续治疗3周。比较2组治疗前、治疗3周后NIHSS评分、日常生活能力评分(BI)、及血清sICAM-1、MCP-1水平,并观察2组治疗效果。结果治疗前2组NIHSS、BI评分差异无统计学意义(P>0.05),治疗3周后与对照组比较,观察组SF-36评分提高,差异有统计学意义(P<0.05);治疗3周后观察组血清sICAM-1、MCP-1水平均低于对照组,差异有统计学意义(P<0.05);观察组总有效率92.31%(48/52)高于对照组75.00%(39/52),差异有统计学意义(P<0.05)。结论予以急性脑梗死患者高压氧联合人尿激肽原酶治疗效果确切,可明显降低患者NIHSS评分及血清sICAM-1、MCP-1水平,减轻其神经功能损伤,提高其日常生活能力。
Objective To investigate the effect of hyperbaric oxygen combined with human urokinase on neurological deficit （NIHSS） and serum soluble intercellular adhesion molecule-1 （sICAM-1）,monocyte chemotaxis protein-1 （MCP-1） levels in patients with acute cerebral infarction （ACI）. Methods From February 2015 to June 2017,104 patients with ACI in our hospital were selected and randomly divided into control group and observation group, each group with 52 cases. The control group was treated with conventional therapy, and the observation group was treated with hyperbaric oxygen combined with human urokinase on the basis of routine treatment, the treatment lasted for 3 weeks. NIHSS score, daily life ability score （BI）, and serum sICAM-1, MCP-1 of the two groups before treatment and 3 weeks after treatment were compared, and therapeutic effect of the two groups were analyzed. Results There was no significant difference in NIHSS and BI scores between the two groups before treatment （P〉0.05）. However,at 3 weeks after the treatment, the NIHSS score of the observation group was decreased and the BI score was improved significantly than that of the control group （P〈0.05） ;the levels of serum sICAM-1 and MCP-1 in the observation group were significantly lower than those in the control group （P〈0. 05）;After treatment, the total effective rate in the observation group was 92. 31% （48/52）, which was higher than that of the control group （75.00%, 39/52）, the difference was statistically significant （P%0.05）. Conclusion Hyperbaric oxygen combined with human urokinase can significantly reduce the NIHSS score and serum slCAM-1, MCP-1 levels, decrease neurological impairment and improve daily living ability and in patients with acute cerebral infarction.
作者
韩苗
张俊士
HAN Miao 1, ZHANG Junshi 2(1.Department of Neurology, Kaifeng Central Hospital, Kaifeng 475000, China ; 2.Huaihe Hospital, Henan University, Kaifeng 475000,Chin)
出处
《中国实用神经疾病杂志》
2018年第6期663-666,共4页
Chinese Journal of Practical Nervous Diseases
基金
河南省教育厅自然科学基金
编号:16A320003
